EXCLUSIVE: Hedge funder Kyle Bass is at war with big pharma, but he's long this one pharma stock
REUTERS/Brendan McDermid
Perrigo (PRGO) is now Hayman Capital's second largest equity position.
This is significant because Bass has been at war with the US pharmaceutical industry since the beginning of this year.
So far this year he's filed 13 inter partes review (IPR) petitions with the US Patent and Trademark Office challenging the patents of six publicly-traded pharma companies.
It's part of a new "short activist strategy" where Bass writes an IPR challenging the validity of a patent, while also shorting the company's stock. For this, Bass has even set up a separate pharmacy vehicle within his fund. The idea is that this will end "pay for delay" for drugmakers and ultimately lower drug prices.
Bass is scheduled to speak at the SALT Conference in Las Vegas. We'll be covering the event, so be sure to check back for updates.
- I spent 2 weeks in India. A highlight was visiting a small mountain town so beautiful it didn't seem real.
- I quit McKinsey after 1.5 years. I was making over $200k but my mental health was shattered.
- Some Tesla factory workers realized they were laid off when security scanned their badges and sent them back on shuttles, sources say
- Stock markets stage strong rebound after 4 days of slump; Sensex rallies 599 pts
- Sustainable Transportation Alternatives
- 10 Foods you should avoid eating when in stress
- 8 Lesser-known places to visit near Nainital
- World Liver Day 2024: 10 Foods that are necessary for a healthy liver